Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + cytarabine + daunorubicin
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of the mTOR inhibitor everolimus and the standard chemotherapy agents cytarabine and daunorubicin. This regimen is being evaluated for the treatment of relapsed acute myeloid leukemia (AML). Everolimus acts as a chemosensitizer by inhibiting the mammalian target of rapamycin (mTOR), a pathway often activated in AML that promotes cell survival and resistance to chemotherapy. Cytarabine is an antimetabolite that inhibits DNA synthesis, while daunorubicin is an anthracycline that causes DNA damage through intercalation and inhibition of topoisomerase II. The combination is designed to enhance the efficacy of the standard "7+3" induction backbone in patients who have failed prior therapy.
- Other names
- Everolimus with Cytarabine and DaunorubicinEverolimus + 7+3 chemotherapyEverolimus + Cytarabine + Daunorubicin hydrochloride
02
Targets
mTOR (Mammalian target of rapamycin kinase)TOP2A (DNA topoisomerase II)DNA polymerase family
Beyond the preview
Go deeper on everolimus + cytarabine + daunorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + cytarabine + daunorubicin.